High levels of B-cell activating factor in patients with active chronic graft-versus-host disease

Clinical Cancer Research

Volumn 13, Issue 20, 2007, Pages 6107-6114

  Sarantopoulos, Stefanie ^a   Stevenson, Kristen E ^a   Kim, Haesook T ^a   Bhuiya, Nazmim S ^a   Cutler, Corey S ^a   Soiffer, Robert J ^a   Antin, Joseph H ^a   Ritz, Jerome ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD STEM CELL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; BLOOD LEVEL; BLOOD TOXICITY; CELL DIFFERENTIATION; CELL SURVIVAL; CHRONIC DISEASE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DRUG MEGADOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; PRIORITY JOURNAL; T LYMPHOCYTE;

ACUTE DISEASE; ADULT; AGED; B-CELL ACTIVATING FACTOR; CELL DIFFERENTIATION; CHRONIC DISEASE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; NEOPLASMS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 35948938957     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1290     Document Type: Article

References (50)

1. Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transplant 2003;9:215-33.
2. Higman MA, Vogelsang GB. Chronic graft versus host disease. Br J Haematol 2004;125:435-54.
3. Majolino I, Saglio G, Scime R, et al. High incidence of chronic GVHD after primary allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies. Bone Marrow Transplant 1996;17:555-60.
4. Socie G, Salooja N, Cohen A, et al. Nonmalignant late effects after allogeneic stem cell transplantation. Blood 2003;101:3373-85.
5. Cutler C, Antin JH. Chronic graft-versus-host disease. Curr Opin Oncol 2006;18:126-31.
6. Deeg HJ, Leisenring W, Storb R, et al. Long-term outcome after marrow transplantation for severe aplastic anemia. Blood 1998;91:3637-45.
7. Goerner M, Gooley T, Flowers ME, et al. Morbidity and mortality of chronic GVHD after hematopoietic stem cell transplantation from HLA-identical siblings for patients with aplastic or refractory anemias. Biol Blood Marrow Transplant 2002;8:47-56.
8. + regulatory T cells in patients with chronic graft-versus-host disease. Blood 2005;106:2903-11.
9. Bhushan V, Collins RH, Jr. Chronic graft-vs-host disease. JAMA 2003;290:2599-603.
10. Ratanatharathorn V, Ayash L, Lazarus HM, Fu J, Uberti JP. Chronic graft-versus-host disease: clinical manifestation and therapy. Bone Marrow Transplant 2001;28:121-9.
11. Shlomchik WD, Lee SJ, Couriel D, Pavletic SZ. Transplantation's greatest challenges: advances in chronic graft-versus-host disease. Biol Blood Marrow Transplant 2007;13 Suppl 1:2-10.
12. Lee S. Chronic graft-versus-host disease. New York: Cambridge University Press; 2004.
13. Biedermann BC, Sahner S, Gregor M, et al. Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease. Lancet 2002;359:2078-83.
14. Mutis T, Gillespie G, Schrama E, Falkenburg JH, Moss P, Goulmy E. Tetrameric HLA class I-minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease. Nat Med 1999;5:839-42.
15. + T and B cells in transplants induce chronic graft-versus-host disease with autoimmune manifestations. Blood 2006;107:2993-3001.
16. Zorn E, Miklos DB, Floyd BH, et al. Minor histocompatibility antigen DBY elicits a coordinated B and T cell response after allogeneic stem cell transplantation. J Exp Med 2004;199:1133-42.
17. Miklos DB, Kim HT, Zorn E, et al. Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors. Blood 2004;103:353-9.
18. Miklos DB, Kim HT, Miller KH, et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood 2005;105:2973-8.
19. Patriarca F, Skert C, Sperotto A, et al. The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recovery. Exp Hematol 2006;34:389-96.
20. Wechalekar A, Cranfield T, Sinclair D, Ganzckowski M. Occurrence of autoantibodies in chronic graft vs. host disease after allogeneic stem cell transplantation. Clin Lab Haematol 2005;27:247-9.
21. Brink R. Regulation of B cell self-tolerance by BAFF. Semin Immunol 2006;18:276-83.
22. Tangye SG, Bryant VL, Cuss AK, Good KL. BAFF, APRIL and human B cell disorders. Semin Immunol 2006;18:305-17.
23. Mariette X, Roux S, Zhang J, et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome. Ann Rheum Dis 2003;62:168-71.
24. Matsushita T, Hasegawa M, Yanaba K, Kodera M, Takehara K, Sato S. Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum 2006;54:192-201.
25. Cheema GS, Roschke V, Hilbert DM, Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 2001;44:1313-9.
26. Thien M, Phan TG, Gardam S, et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 2004;20:785-98.
27. Goodnow CC, Cyster JG, Hartley SB, et al. Self-tolerance checkpoints in B lymphocyte development. Adv Immunol 1995;59:279-368.
28. Cyster JG, Goodnow CC. Antigen-induced exclusion from follicles and anergy are separate and complementary processes that influence peripheral B cell fate. Immunity 1995;3:691-701.
29. Avery DT, Kalled SL, Ellyard JI, et al. BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J Clin Invest 2003;112:286-97.
30. Zhang J, Roschke V, Baker KP, et al. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 2001;166:6-10.
31. Gorelik L, Gilbride K, Dobles M, Kalled SL, Zandman D, Scott ML. Normal B cell homeostasis requires B cell activation factor production by radiation-resistant cells. J Exp Med 2003;198:937-45.
32. Groh V, Li YQ, Cioca D, et al. Efficient cross-priming of tumor antigen-specific T cells by dendritic cells sensitized with diverse anti-MICA opsonized tumor cells. Proc Natl Acad Sci U S A 2005;102:6461-6.
33. Hon H, Oran A, Brocker T, JacobJ . B lymphocytes participate in cross-presentation of antigen following gene gun vaccination. J Immunol 2005;174:5233-42.
34. + T-cell priming in vivo. Blood 2006;107:594-601.
35. von Bergwelt-Baildon MS, Vonderheide RH, Maecker B, et al. Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application. Blood 2002;99:3319-25.
36. Ueda Y, Yang K, Foster SJ, Kondo M, Kelsoe G. Inflammation controls B lymphopoiesis by regulating chemokine CXCL12 expression. J Exp Med 2004;199:47-58.
37. Schneider P. The role of APRIL and BAFF in lymphocyte activation. Curr Opin Immunol 2005;17:282-9.
38. Arce S, Luger E, Muehlinghaus G, et al. CD38 low IgG-secreting cells are precursors of various CD38 high-expressing plasma cell populations. J Leukoc Biol 2004;75:1022-8.
39. Carter RH, Zhao H, Liu X, et al. Expression and occupancy of BAFF-R on B cells in systemic lupus erythematosus. Arthritis Rheum 2005;52:3943-54.
40. Gottenberg JE, Pallier C, Ittah M, et al. Failure to confirm coxsackievirus infection in primary Sjogren's syndrome. Arthritis Rheum 2006;54:2026-8.
41. Nakamura N, Hase H, Sakurai D, et al. Expression of BAFF-R (BR 3) in normal and neoplastic lymphoid tissues characterized with a newly developed monoclonal antibody. Virchows Arch 2005;447:53-60.
42. Sellam J, Miceli-Richard C, Gottenberg JE, et al. Decreased BAFF-R on peripheral lymphocytes associated with increased disease activity in primary Sjogren's syndrome and systemic lupus erythematosus. Ann Rheum Dis 2006;66:790-7.
43. Lee SJ. New approaches for preventing and treating chronic graft-versus-host disease. Blood 2005;105:4200-6.
44. Atkinson K. Chronic graft-versus-host disease. Bone Marrow Transplant 1990;5:69-82.
45. Edwards JC, Cambridge G. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol 2006;6:394-403.
46. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximabi n patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-81.
47. Okamoto H, Kamatani N. Rituximab for rheumatoid arthritis. N Engl J Med 2004;351:1909; author reply.
48. Ratanatharathorn V, Ayash L, Reynolds C, et al. Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biol Blood Marrow Transplant 2003;9:505-11.
49. Cutler C, Miklos D, Kim HT, et al. Rituximab for steroid-refractory chronic graft-vs.-host disease. Blood 2006;108:756-62.
50. Okamoto M, Okano A, Akamatsu S, et al. Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease. Leukemia 2006;20:172-3.